55.70
전일 마감가:
$56.45
열려 있는:
$56.49
하루 거래량:
502.18K
Relative Volume:
0.20
시가총액:
$6.87B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
18.44
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
-3.24%
1개월 성능:
+5.62%
6개월 성능:
-0.29%
1년 성능:
+3.22%
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
HALO
Halozyme Therapeutics Inc
|
55.72 | 7.10B | 947.36M | 392.47M | 392.71M | 3.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.50 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.49 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
321.13 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
567.20 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
290.51 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-10 | 재개 | Goldman | Neutral |
2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2024-02-29 | 개시 | TD Cowen | Outperform |
2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
2023-07-24 | 개시 | H.C. Wainwright | Buy |
2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2023-03-27 | 재개 | Berenberg | Buy |
2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
2022-12-21 | 재개 | Morgan Stanley | Overweight |
2022-11-28 | 개시 | Wells Fargo | Overweight |
2022-09-09 | 개시 | Morgan Stanley | Overweight |
2022-05-23 | 개시 | SVB Leerink | Outperform |
2021-06-14 | 개시 | Evercore ISI | Outperform |
2021-05-17 | 개시 | SVB Leerink | Outperform |
2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2021-01-21 | 재확인 | The Benchmark Company | Buy |
2020-12-17 | 개시 | Berenberg | Buy |
2020-09-14 | 재개 | JP Morgan | Overweight |
2020-07-01 | 개시 | The Benchmark Company | Buy |
2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2020-01-08 | 개시 | Goldman | Buy |
2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
2018-10-19 | 재개 | Piper Jaffray | Neutral |
2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
2018-01-24 | 개시 | Goldman | Neutral |
2017-10-16 | 재확인 | Piper Jaffray | Overweight |
2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
2016-11-03 | 개시 | Deutsche Bank | Buy |
2015-12-04 | 개시 | Wells Fargo | Outperform |
2015-11-18 | 개시 | Citigroup | Buy |
2015-09-22 | 개시 | Barclays | Overweight |
2015-06-22 | 재확인 | JP Morgan | Overweight |
2015-03-03 | 재확인 | UBS | Buy |
2015-02-18 | 재확인 | MLV & Co | Buy |
2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
What analysts say about Halozyme Therapeutics Inc. stockConsistent high-yield stocks - jammulinksnews.com
Is Halozyme Therapeutics Inc. a good long term investmentTremendous wealth creation - jammulinksnews.com
What drives Halozyme Therapeutics Inc. stock priceExplosive capital gains - jammulinksnews.com
Halozyme Therapeutics Inc. Stock Analysis and ForecastFree Stock Market Beginners Guide - PrintWeekIndia
Published on: 2025-07-18 13:49:29 - jammulinksnews.com
Investor Network: Halozyme Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $60.00 - MarketBeat
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance
How Halozyme Therapeutics Inc. stock performs during market volatilityFree AI-Powered Stock Predictions - beatles.ru
Halozyme Therapeutics: A 20% CAGR Growth Story Powered by ENHANZE, Litigation Upside, and Undervalued M&A Potential - AInvest
Halozyme Therapeutics' strategic adoption - MarketScreener
Halozyme Therapeutics (HALO): Navigating Regulatory Crosscurrents to Seize Long-Term Value - AInvest
Halozyme Therapeutics Downgraded Amid Concerns Over Long-Term Value. - AInvest
Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade) (HALO) - Seeking Alpha
Halozyme Therapeutics: CEO Stock Sales vs. Robust Pipeline and Financial Momentum - AInvest
Halozyme (HALO) CEO Torley sells $3.4 million in stock after option exercises By Investing.com - Investing.com South Africa
Halozyme (HALO) CEO Torley sells $3.4 million in stock after option exercises - Investing.com Nigeria
Halozyme stock resumes coverage at Goldman Sachs with Neutral rating By Investing.com - Investing.com Canada
Goldman Sachs Resumes Coverage of Halozyme (HALO) with Neutral R - GuruFocus
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years - Benzinga
Halozyme Therapeutics Added to Russell 1000® Index - Eastern Progress
Why Halozyme Therapeutics, Inc. (HALO) Skyrocketed On Wednesday - MSN
Halozyme Therapeutics (HALO): A Momentum Stock to Consider - AInvest
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term - Yahoo Finance
Halozyme Therapeutics Added to Russell 1000® Index | HALO Stock News - GuruFocus
Halozyme Therapeutics: A Catalyst-Fueled Ascension to the Russell 1000 - AInvest
Halozyme therapeutics added to Russell 1000 index By Investing.com - Investing.com South Africa
Halozyme therapeutics added to Russell 1000 index - Investing.com
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - The Malaysian Reserve
Breakthrough for CIDP Patients: EU Green Lights First Novel Treatment in 3 DecadesHalozyme Partnership Delivers - Stock Titan
Therapeutics (NASDAQ:HALO) Stock Nasdaq Composite - Kalkine Media
Investors in Halozyme Therapeutics (NASDAQ:HALO) have seen impressive returns of 107% over the past five years - simplywall.st
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock - Yahoo Finance
Halozyme Therapeutics: The Waters Become Muddled (NASDAQ:HALO) - Seeking Alpha
Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today - Benzinga
H.C. Wainwright Reiterates Buy on Halozyme (HALO), Maintains Price Target - MSN
Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline - MSN
TD Cowen reiterates buy rating on Halozyme stock amid CMS impact analysis - Investing.com Canada
Halozyme at Goldman Sachs Conference: Subcutaneous Innovation Drives Growth - Investing.com
Halozyme at Goldman Sachs Conference: Subcutaneous Innovation Drives Growth By Investing.com - Investing.com Nigeria
Transcript : Halozyme Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener
Merck gains U.S. patent office support in Keytruda dispute - MSN
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - mx.advfn.com
Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? - Yahoo Finance
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Halozyme Therapeutics Inc 주식 (HALO) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Torley Helen | PRESIDENT AND CEO |
Jul 09 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
Torley Helen | PRESIDENT AND CEO |
Jul 10 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
Torley Helen | PRESIDENT AND CEO |
Jul 10 '25 |
Sale |
57.43 |
20,000 |
1,148,618 |
733,719 |
Torley Helen | PRESIDENT AND CEO |
Jul 09 '25 |
Sale |
56.43 |
20,000 |
1,128,655 |
733,719 |
Torley Helen | PRESIDENT AND CEO |
Jul 08 '25 |
Sale |
55.51 |
20,000 |
1,110,245 |
733,719 |
Torley Helen | PRESIDENT AND CEO |
Jun 20 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
Torley Helen | PRESIDENT AND CEO |
Jun 24 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
Torley Helen | PRESIDENT AND CEO |
Jun 23 '25 |
Option Exercise |
8.11 |
20,000 |
162,200 |
753,719 |
Torley Helen | PRESIDENT AND CEO |
Jun 24 '25 |
Sale |
53.73 |
20,000 |
1,074,620 |
733,719 |
Torley Helen | PRESIDENT AND CEO |
Jun 20 '25 |
Sale |
52.96 |
20,000 |
1,059,200 |
733,719 |
자본화:
|
볼륨(24시간):